Gsa Capital Partners LLP Catalyst Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

$1.11 Billion
Q1 2025

A detailed history of Gsa Capital Partners LLP transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 22,584 shares of CPRX stock, worth $534,563. This represents 0.05% of its overall portfolio holdings.

Number of Shares

22,584

Previous 62,887 64.09%

Holding current value

$534,563

Previous $1.31 Million 58.23%

% of portfolio

0.05%

Previous 0.1%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	SELL	$19.53 - $25.74 $787,117 - $1.04 Million	-40,303 Reduced 64.09%	22,584 $548,000
Q4 2024 Feb 07, 2025	BUY	$19.73 - $23.93 $620,508 - $752,598	31,450 Added 100.04%	62,887 $1.31 Million
Q3 2024 Nov 05, 2024	BUY	$15.19 - $21.35 $477,528 - $671,179	31,437 New	31,437 $625,000
Q1 2024 May 03, 2024	BUY	$13.18 - $17.11 $788,664 - $1.02 Million	59,838 New	59,838 $953,000
Q2 2022 Aug 09, 2022	BUY	$6.23 - $8.57 $435,670 - $599,308	69,931 Added 192.96%	106,172 $744,000
Q1 2022 May 11, 2022	BUY	$5.31 - $8.31 $65,382 - $102,321	12,313 Added 51.46%	36,241 $300,000
Q4 2021 Feb 14, 2022	BUY	$5.21 - $7.45 $124,664 - $178,263	23,928 New	23,928 $162,000
Q3 2021 Nov 12, 2021	SELL	$4.85 - $6.04 $115,696 - $144,084	-23,855 Closed	0 $0
Q2 2021 Aug 05, 2021	SELL	$4.29 - $6.05 $287,580 - $405,561	-67,035 Reduced 73.75%	23,855 $137,000
Q1 2021 May 10, 2021	SELL	$3.45 - $4.69 $33,516 - $45,563	-9,715 Reduced 9.66%	90,890 $419,000
Q4 2020 Feb 03, 2021	BUY	$2.97 - $3.83 $298,796 - $385,317	100,605 New	100,605 $336,000
Q2 2020 Aug 11, 2020	SELL	$3.48 - $5.05 $298,166 - $432,684	-85,680 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$2.61 - $5.21 $265,739 - $530,461	-101,816 Reduced 54.3%	85,680 $330,000
Q4 2019 Feb 12, 2020	BUY	$3.67 - $5.7 $560,988 - $871,290	152,858 Added 441.3%	187,496 $703,000
Q3 2019 Nov 12, 2019	BUY	$3.89 - $7.43 $32,746 - $62,545	8,418 Added 32.11%	34,638 $184,000
Q2 2019 Aug 06, 2019	BUY	$2.7 - $6.11 $70,794 - $160,204	26,220 New	26,220 $101,000
Q4 2018 Feb 12, 2019	SELL	$1.92 - $3.62 $389,462 - $734,298	-202,845 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$2.81 - $3.78 $499,505 - $671,932	-177,760 Reduced 46.7%	202,845 $767,000
Q2 2018 Aug 09, 2018	BUY	$2.26 - $3.84 $642,764 - $1.09 Million	284,409 Added 295.66%	380,605 $1.19 Million
Q1 2018 May 11, 2018	BUY	$2.39 - $4.01 $229,908 - $385,745	96,196 New	96,196 $230,000
Q4 2017 Feb 14, 2018	SELL	$2.51 - $4.4 $1.2 Million - $2.11 Million	-479,196 Closed	0 $0
Q3 2017 Nov 20, 2017	BUY	$2.4 - $2.94 $1.15 Million - $1.41 Million	479,196	479,196 $1.21 Million

Others Institutions Holding CPRX

# of Institutions

389

Shares Held

99.3M

Call Options Held

37K

Put Options Held

20.5K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.43B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP Catalyst Pharmaceuticals, Inc. Transaction History